zanubrutinib + ixazomib + dexamethasone

Zanubrutinib + ixazomib + dexamethasone is an investigational combination therapy evaluated primarily for the treatment of newly diagnosed Waldenström macroglobulinemia (WM), a rare type of lymphoma. The regimen combines three agents with distinct mechanisms: - Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor, disrupting B-cell receptor signaling and inhibiting malignant B-cell proliferation. - Ixazomib is an oral proteasome inhibitor that blocks the 20S proteasome, leading to accumulation of misfolded proteins and apoptosis in cancer cells. - Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects, commonly used as part of antineoplastic regimens. In phase 2 clinical trials (NCT04463953), this combination demonstrated high overall response rates and deep remission in WM patients, offering a time-limited BTKi-based therapy. The most common adverse events were hematological toxicities[1][6][2].

Other names

ZID regimen